Insmed (INSM) Net Income towards Common Stockholders (2010 - 2026)

Insmed's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$163.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 36.25% year-over-year to -$163.6 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 16.83% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.73% from the prior year.
• Net Income towards Common Stockholders was -$163.6 million for Q1 2026 at Insmed, up from -$328.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$94.6 million in Q1 2022 to a low of -$370.0 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$210.9 million across 5 years, with a median of -$186.1 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders sank 155.96% in 2023, then jumped 36.25% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$160.1 million in 2022, then retreated by 16.2% to -$186.1 million in 2023, then decreased by 26.6% to -$235.5 million in 2024, then sank by 39.46% to -$328.5 million in 2025, then surged by 50.21% to -$163.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$163.6 million (Q1 2026), -$328.5 million (Q4 2025), and -$370.0 million (Q3 2025), per Business Quant data.